QM protein - protein search, using sw model

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

Run on: November 27, 2002, 05:38:32 ; Search time 58.5251 Seconds
(without alignments)
241.342 Million cell updates/sec

Title: US-09-893-615-89
Perfect score: 556
Sequence: 1 QIVLSQSPAILSASPGEKVT..........CQQWSSNPPTFGGGTMLEIR 106

Searched: 908470 seqs, 133250620 residues

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Total number of hits satisfying chosen parameters: 908470

Post-processing: Minimum Match 0%
Minimum DB seq length: 0
Maximum DB seq length: 200000000
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002.*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

ALIGNMENTS

No.	Score	% Query Match	Length	DB	ID	Description
11	516	92.8	128	10	AAP94781	2 H7 VL gene, Syn
12	516	92.8	128	18	AAW10589	2H7 antibody ligh
13	516	92.8	128	18	AAW16344	2H7 light chain va
14	516	92.8	128	18	AAW10243	2H7 light chain va
15	516	92.8	128	19	AAW47521	Light chain variab
16	516	92.8	128	19	AAW41071	Mouse 2H7 antibody
17	516	92.8	128	19	AAW47514	Mouse 2H7 antibody
18	516	92.8	128	22	AAW89541	Mouse 2H7 antibody
19	514	92.4	633	21	AAY84965	2H7 light chain va
20	514	92.4	129	21	AAR20789	Mouse antibody 2H7
21	507	91.2	129	13	AAW82740	Amino acid sequenc
22	507	91.2	235	17	AAW82746	Unprocessed variab
23	507	91.2	235	20	AAB08025	A5B7 antibody ligh
24	507	91.2	235	13	AAW06178	Murine A5B7 light
25	507	91.2	235	20	AAR15323	Plasmid pNG3/A5B7v
26	507	91.2	235	21	AAR32127	Plasmid pEE14/A5B7
27	507	91.2	235	14	AAU72834	A dimeric anti-CD2
28	504	90.6	145	18	AAW19914	IL-2 chimeric anti
29	503	90.5	145	12	AAR79883	Anti-IL2R-alpha an
30	501	90.1	105	18	AAR45442	Anti-NKG2D hybrido
31	491	88.3	108	16	AAR94020	Kappa light chain
32	489	87.9	236	15	AAW15185	Anti-EGFR antibody
33	489	87.9	108	16	AAR34263	Sequence of the S1
34	489	87.9	237	18	AAR60522	Anti-erbB2 scFv.
35	486	87.4	107	14	AAR99874	Single-chain anti-
36	486	87.4	246	15	AAI33426	Mab32 V-gene heavy
37	484	87.1	252	21	AAY79059	Anti-TNF diabody D
38	484	87.1	252	22	AAB36825	Chimeric L6 anti-t
39	482	86.7	237	21	AAY24723	L6 sFv protein. U
40	478	86.0	107	13	AAR07317	Amino acid sequenc
41	475	85.4	107	11	AAW14485	Sequence encoded b
42	475	85.4	97	11	AAR24732	VK domain of antib
43	475	85.4	97	17	AAR07317	Monoclonal antibod
44	475	85.4	97	20	AAI33426	Monoclonal antibod
45	475	85.4	97	21	AAY51369	Mouse antibody MAK
	475	85.4	97	21		Mouse monoclonal a

RESULT 1

AAW24532

AAW24532 standard; Protein; 106 AA.

```
ID   AAW24532 standard; Protein; 106 AA.
XX
AC   AAW24532;
XX
DT   27-DEC-1997 (first entry)
XX
DE   Anti-Factor IX MAb chimeric light chain.
XX
KW   Thrombosis; therapy; Factor IX; anticoagulant; monoclonal antibody;
KW   chimeric antibody; antibody engineering; light chain.
XX
OS   Chimeric Mus musculus.
OS   Chimeric Homo sapiens.
OS   Chimeric synthetic.
XX
PN   WO9726010-A1.
XX
PD   24-JUL-1997.
XX
PF   17-JAN-1997; 97WO-US00759.
XX
PR   24-OCT-1996; 96US-0029119.
PR   17-JAN-1996; 96US-0010108.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
PA   (UIVE-) UNIV VERMONT & STATE AGRIC COLLEGE.
XX
PI   Blackburn MN, Church WR, Feuerstein GZ, Gross MS;
PI   Nichols AJ, Padian EA, Patel AH, Sylvester LF;
XX
DR   WPI; 1997-385117/35.
```

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	526	94.6	106	18	AAW24532	Anti-Factor IX MAb
2	526	94.6	106	23	AAW10589	Mouse-human light
3	526	94.6	107	18	AAU81002	Mouse anti-human
4	526	94.6	107	23	AAW24520	Mouse anti-human F
5	526	94.6	112	18	AAU80976	Murine BC2 light c
6	526	94.6	112	23	AAW24531	Anti-Factor IX MAb
7	521	93.7	112	23	AAU81001	Murine BC2 light
8	521	93.7	128	15	AAR55214	Murine variable re
9	517	93.0	412	22	AAB30694	A fusion of anti;
10	517	93.0	423	22	AAB30695	A fusion of anti-C
	516	92.8	128	8	AAP70628	Sequence encoded b

DR N-PSDB; AAT79900.
XX
PT Inhibiting thrombosis with self-limiting antibody to coagulation
PT factor - avoids uncontrolled bleeding by providing only partial
PT inhibition
XX
PT Example 7; Page 128; 150pp; English.
XX
PS Sequence   106 AA;
SQ
CC This polypeptide comprises a mouse-human chimeric antibody
CC light chain in which the variable region is derived from mouse
CC anti-human factor IX monoclonal antibody BC2 (see AAW24531) and
CC human sequences from the immunoglobulin RF-TS3'CL framework.
CC It can be expressed in transfected mammalian cells utilising a
CC cDNA construct (see AAT79900) obtained by PCR amplification (see
CC AAT79897-98) of BC2 cDNA and insertion of the PCR product into
CC F9H2HC 1-3 cDNA (see AAT77374). Claimed anti-Factor IX chimeric
CC antibodies are useful in the treatment of thrombosis.
XX

Query Match   94.6%;
Best Local Similarity   95.3%;   Pred. No. 1.8e-30;
Matches 101; Conservative   1; Mismatches   4; Indels   0; Gaps   0;

```
Qy  1 QIVLSQSPAILSASPGEKVTMTCRASSSVNYMHWYQQKPGSSPKPWISATSNLASGVPAR 60
      ||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db  1 QIVLSQSPAILSASPGEKVTMTCRASSSVNYMHWYQQKPGSSPKPWIYATSNLASGVPAR 60

Qy 61 FSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPPTFGGGTIMLEIR 106
      ||||||||||||||||||||||||||| ||| ||| ||| |||||
Db 61 FSGSGSGTSYSLTISRVEAEDAATYYCQQWSINPRTFGGGTKLEIK 106
```

RESULT 2
AAU81002
ID AAU81002 standard; Protein; 106 AA.
XX
AC AAU81002;
XX
DT 09-APR-2002 (first entry)
XX
DE Mouse-human light chain polypeptide.
XX
KW Human; mouse; BC2; animal post-thromboembolic induced ischaemia;
KW thrombolytic agent; anti-factor IX antibody; plasminogen activator;
KW thromboembolic stroke; cerebroprotective; anticoagulant; Thrombolytic;
KW vasotropic; cardiant; anti-respiratory syncytial virus;
KW heavy chain variable region; light chain variable region.
XX
OS Chimeric - Mus sp.
OS Chimeric - Homo sapiens.
XX
PN WO200187339-A1.
XX
PD 22-NOV-2001.
XX
PF 05-OCT-2000; 2000WO-US27438.
XX
PR 15-MAY-2000; 2000US-0571434.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
XX
PI Barone FC, Blackburn MN, Feuerstein GZ, Toomey JR;
XX
DR WPI; 2002-082944/11.
DR N-PSDB; ABK24005.
XX
PT Treating post-thromboembolic induced ischaemia in an animal by
PT administering anti-factor IX antibody in combination with a plasminogen
PT activator -
XX
PS Example 7; Page 155-156; 163pp; English.

CC The invention relates to a method for treating an animal
CC post-thromboembolic induced ischaemia or reducing a required dose of a
CC thrombolytic agent in treatment of an animal post-thromboembolic induced
CC ischaemia, comprising administering an anti-factor IX antibody or its
CC fragment, optionally in combination with a plasminogen activator or
CC thrombolytic agent. The method is useful for treating
CC post-thromboembolic-induced ischaemia, for preventing thromboembolic
CC stroke in an animal, and for reducing a required dose of a thrombolytic
CC agent. Sequences AAU80972-AAU81004 represent antibodies and vector
CC polypeptides used in the method of the invention.
XX
SQ Sequence   106 AA;

Query Match   94.6%;
Best Local Similarity   95.3%;   Pred. No. 1.8e-30;
Matches 101; Conservative   1; Mismatches   4; Indels   0; Gaps   0;

```
Qy  1 QIVLSQSPAILSASPGEKVTMTCRASSSVNYMHWYQQKPGSSPKPWISATSNLASGVPAR 60
      ||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db  1 QIVLSQSPAILSASPGEKVTMTCRASSSVNYMHWYQQKPGSSPKPWIYATSNLASGVPAR 60

Qy 61 FSGSGSGTSYSLTISRVEAEDAATYYCQQWSSNPPTFGGGTIMLEIR 106
      ||||||||||||||||||||||||||| ||| ||| ||| |||||
Db 61 FSGSGSGTSYSLTISRVEAEDAATYYCQQWSINPRTFGGGTKLEIK 106
```

RESULT 3
AAW24520
ID AAW24520 standard; Protein; 107 AA.
XX
AC AAW24520;
XX
DT 26-DEC-1997 (first entry)
XX
DE Mouse anti-human Factor IX antibody BC2 light chain variable region.
XX
FH Key   Location/Qualifiers
FH -
FT Region   24..33
FT   /label= CDR1
FT   /note= "(Claim 23)"
FT Region   49..55
FT   /label= CDR2
FT   /note= "(Claim 23)"
FT Region   88..96
FT   /label= CDR3
FT   /note= "(Claim 23)"
XX
OS Mus musculus.
XX
KW Thrombosis; therapy; Factor IX; anticoagulant; monoclonal antibody;
KW humanised antibody; antibody engineering; light chain; CDR;
KW complementarity determining region; stroke; myocardial infarction;
KW angina; atrial fibrillation; deep vein thrombosis; coronary angioplasty;
KW pulmonary embolism; kidney damage;
KW disseminated intravascular coagulation; artificial organ; sepsis;
KW shunt; prosthesis.
XX
PN WO9726010-A1.
XX
PD 24-JUL-1997.
XX
PF 17-JAN-1997; 97WO-US00759.
XX
PR 24-OCT-1996; 96US-0029119.
PR 17-JAN-1996; 96US-0010108.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
PA (UVE-) UNIV VERMONT & STATE AGRIC COLLEGE.
XX
PI Blackburn MN, Church WR, Feuerstein GZ, Gross MS;
PI Nichols AJ, Padlan EA, Patel AH, Sylvester DR;
XX
DR WPI; 1997-385117/35.